Abstract: Rifaximin, with its low systemic absorption, may represent a treatment of choice for irritable bowel syndrome (IBS), mainly due to its ability to act on IBS pathogenesis, through the influence on gut microbiota. The aim of the present study was to assess, by biomolecular tools, the rifaximin active modulation exerted on gut microbiota of non-constipated IBS patients. Fifteen non-constipated IBS subjects were treated with 550 mg rifaximin three times a day for 14 days. Stool samples were collected before starting the treatment, at the end of it, and after a 6-week washout period. Real-time polymerase chain reaction, denaturing gradient gel electrophoresis, and next-generation sequencing were applied to all the samples to verify and quantify possible microbial fluctuations. Rifaximin treatment did not affect the overall composition of the microbiota of the treated subjects, inducing fluctuations in few bacterial groups, balanced by the replacement of homologs or complementary bacterial groups. Rifaximin appeared to influence mainly potentially detrimental bacteria, such as Clostridium, but increasing the presence of some species, such as Faecalibacterium prausnitzii. A decrease in the Firmicutes/ Bacteroidetes ratio after 14 days of treatment and bacterial profiles with higher biodiversity were observed during the follow-up compared to baseline. Rifaximin treatment, although effective on IBS symptom relief and normalization of lactulose breath test, did not induce dramatic shifts in the microbiota composition of the subjects, stimulating microbial reorganization in some populations toward a more diverse composition. It was not possible to speculate on differences of fecal microbiota modification between responders vs nonresponders and to correlate the quali-/ quantitative modification of upper gastrointestinal microbiota and clinical response.
Introduction
Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by chronic recurrent abdominal pain or discomfort associated with disordered bowel habits. 1 No single unifying cause has been identified for IBS, but there is recent evidence suggesting the involvement of the gut microbiota. In particular, imbalances in gut microbiota have been suggested to contribute to IBS and IBS-related symptoms. 2 The role of the intestinal microbiota in the pathophysiology of IBS was investigated in several studies. Early studies using selective and nonselective culture techniques demonstrated differing viable levels of coliforms, Lactobacillus, Bifidobacteria and Enterobacteriaceae species in fecal samples from IBS patients. [3] [4] [5] More recent studies, using molecular methods, characterized an abnormality or dysbiosis in the intestinal microbiota of IBS subjects and demonstrated variations in the levels of the Rifaximin is a nonabsorbable, oral antibiotic derived from rifamycin, which has a broad spectrum of activity against gram-positive and gram-negative, aerobic, and anaerobic Enterobacteria. 12 Recently, rifaximin treatment at the dose of 550 mg three times a day for 14 days was shown to induce a durable relief of symptoms from non-constipated IBS (non-C IBS). 13 Other published clinical studies with rifaximin at 1,000 to 1,200 mg/day for approximately 10 days was shown to be effective in terms of IBS symptoms' improvement and it was even associated with reduction in small intestinal bacterial overgrowth (SIBO) as diagnosed by hydrogen breath test. [14] [15] [16] [17] [18] [19] [20] [21] [22] The aim of this exploratory study was, therefore, to evaluate the effect and the impact on gut microbiota, in terms of composition and diversity of fecal microbial community, after rifaximin treatment in patients with non-C IBS, using different molecular techniques, such as polymerase chain reaction (PCR)-Denaturing Gradient Gel Electrophoresis (DGGE) and highthroughput sequencing technologies. These techniques allow, in fact, a deeper characterization of bacterial communities such as the microflora of the GI tract. In particular, Illumina sequencing was chosen as a very powerful and up-to-date tool to improve the knowledge of complex environment composition.
Furthermore a possible correlation with clinical symptoms was secondarily investigated.
Materials and methods
This exploratory, open label study was conducted at the Internal Medicine and Gastroenterology Division, Catholic University of Rome, between May 2011 and June 2012. The protocol was approved by the Comitato Etico Indipendente of the Catholic University of Rome (Italy) Ethics Committee, and all patients gave written informed consent. The study was conducted according to the European Clinical Trials Directive (EudraCT number: 2010-024177-39).
study population
We studied 15 non-C IBS patients and five healthy subjects (HS). Only non-C IBS patients received treatment with rifaximin 550 mg tablets three times a day for 14 days. Healthy volunteers did not receive any study drug.
HS were of either sex, aged between 18 and 75 years without concomitant diseases or recurring GI symptoms and no clinically significant abnormalities.
Non-C IBS patients (according to Rome II diagnostic criteria) 23 with current symptoms of IBS aged between 18 and 75 years were enrolled. Patients were excluded if they had constipation-predominant IBS, inflammatory bowel disease, diabetes or unstable thyroid disease, history of duodenal or gastric ulcer, diverticulitis or infectious gastroenteritis, previous abdominal surgery or known hypersensitivity to rifaximin/rifampin or excipients, lactose intolerance, positive stool culture for pathogenic bacteria, yeast, parasites and viruses, human immunodeficiency virus infection and renal, or cardiac or hepatic disease. Subjects treated with rifaximin and other antibiotics, probiotics, antipsychotics, antispasmodics, bismuth subsalicylate or Kaopectate, alosetron, laxatives, lubiprostone, proton-pump inhibitors, narcotics, prokinetic drugs within 4 weeks prior to and during screening were also excluded from the study.
Subjects could receive no more than 3 consecutive days of treatment with nonsteroidal anti-inflammatory drugs during the study. Tricyclic antidepressants and serotonin reuptake inhibitors were allowed at stable doses for at least 6 weeks prior to screening throughout the duration of the study.
study design and procedures
Following the screening procedures to exclude any concomitant disease, the involvement of HS into the study was limited to the collection of one fecal sample.
Rifaximin 550 mg tablets were administered orally three times per day for 14 days to non-C IBS patients. Patients were followed for an additional 6 weeks. Before baseline assessment, patients underwent a 2-week screening period. Non-C IBS patients were administered an IBS symptom binary questionnaire each week during the treatment and the 6-week follow-up period, in order to assess IBS symptom improvement. Fecal sample collection and lactulose breath test (LBT) were performed at baseline (T0), at the end of 14 days of treatment, and at the end of the 6-week follow-up period (T56).
Adverse events were monitored throughout the study. The duration and intensity of each event were recorded by the investigator, together with its relationship to the study drug, and its outcome and seriousness. Standard laboratory tests, including hematology, biochemistry, and urinalysis were performed at screening, at the end of the treatment (T14), and at the end of the follow-up (T56).
Efficacy variables
The key clinical end point was the proportion of patients who achieved adequate relief of global IBS symptoms. This end point was determined from the response (yes or no) to the following question, which was asked weekly during the evaluation 
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non-constipated iBs subjects treated with rifaximin period (ie, weeks 2 through 5): "In regard to all your symptoms of IBS, as compared with the way you felt before you started the study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms?". Other clinical end points were the proportion of patients reporting adequate relief of bloating, abdominal pain/discomfort during the same period.
Bacterial community Dna extraction
The collected fecal samples were frozen immediately at −30°C and stored until used. Fecal bacterial DNA was extracted using the FastDNA SPIN Kit and FastPrep Instrument (MP Biomedicals, Santa Ana, CA, USA). The extracted DNA was quantified using the PicoGreen method of the Quant-iT™ HS ds-DNA assay kit in a Qubit™ fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) and verified.
Quantitative PCr
Real-time PCR (RT-PCR) was performed in epGradientS, RealPlex4 instrument (Eppendorf, Amburg, Germany), and SYBR Green I fluorophore was used to correlate the amount of PCR product with the fluorescence signal. Specific primers for the quantification of 16S rRNA gene belonging to some of the most interesting phyla/genera constituting the gut microbiota, ie, Bifidobacteria, Enterobacteriaceae, Firmicutes, and Bacteroidetes, were used as previously reported. [24] [25] [26] For all the samples, the amount of DNA was adjusted to the same concentration of 3 ng/µL to avoid quantification biases, and the final results were converted to correspond to the bacterial load found in 1 g of wet feces.
PCr-DGGE analysis
Two primers designed on the 16SrDNA molecules, Bact0124-GCf and Univ0515r were chosen. The amplification was performed following the indications reported by Heilig et al. 27 Dice's and Pearson's coefficients were calculated applying the specific software InfoQuest TM FP Software (Bio-Rad Laboratories Inc., Hercules, CA, USA) and the sequences of the isolated fragments were compared to those available in public databases by using Basic Local Alignment Search Tool analysis of sequences from Ribosomal Database Project. 28 Multiplexed high-throughput sequencing of the prokaryotic 16s rrna gene PCr amplicons
The V3-4 hypervariable region PCR amplicons and the V5-6 hypervariable region PCR amplicons of the bacterial and archaeal 16S rRNA gene, respectively, were screened using an Illumina platform multiplex approach. 29 The amplification, 
statistical analysis
The full analysis and safety sets of data included all patients randomized who received at least one dose of study medication and who had at least one post-baseline safety assessment.
Demographic variables and baseline disease factors
The number and proportion of subjects with normalization of LBT at the end of treatment and at the end of the follow-up and with and without adequate relief of global IBS symptoms, abdominal pain/discomfort, and bloating each week during the study were summarized by means of descriptive statistics. 34 package, unless otherwise stated, were used for the rest analysis tests. The generated amplicon reads per sample were down-sampled to the sequences for the sample represented by the lowest number of reads per targeted microbial group, to reduce biases associated with potentially undetected sequencing artefacts 32 and also the sample size effect on the α and β diversity indices. 35 The sequence data analysis was performed through the operational taxonomic unit (OTU) and the taxonomy-based approaches. The OTU and taxonomy matrices were used to assess the associated α and β diversity of the analyzed samples. Calculated α diversity indices included the inverse Simpson's index (D). 36 Core microbiome analysis was performed in order to identify OTUs consistently occurring for each sampling, defined as sequences with relative abundances of at least 1% in 60% of the samples. Differences between samples and testing experiment-associated hypotheses were analyzed through clustering analysis and multivariate approaches. Dominant OTUs and taxa were further analyzed for differential abundances and correlations between treatments and time using Student's t-test-based pairwise comparisons of the Metastats R package 37 and rank correlations. Interesting sequences were subjected to maximum likelihood phylogenies along with type isolate partial 16S rRNA gene sequences using the RAxML-HPC v7.2.8 software.
Microbiological analysis
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Results
Characteristics of the subjects
Five HS (one male and four females), with a mean age (± SD) of 27.7±8.2 years (range: 22-44) and 15 patients with non-C IBS (five males and ten females) with a mean age (± SD) of 34.5±14.5 years (range: 19-62) were enrolled. All HS and patients were of Caucasian origin. None of the enrolled patients and HS were taking concomitant medications during the month before the screening visit and during the study. Stool culture for pathogenic bacteria, yeast, parasites, and viruses performed before the first drug intake were negative in all enrolled HS and patients. The compliance to study drug was higher than 90% in all patients. All the patients completed the entire 56-day study period. At baseline (T0), 12 of the 15 non-C IBS patients had a diagnosis of SIBO confirmed by an LBT.
Efficacy
Of the patients, 80% (12/15) met the criteria for the key clinical end point of adequate relief of global IBS symptoms during the evaluation period. Patients with adequate relief of global IBS symptoms also reported adequate relief of bloating and abdominal pain/discomfort. In regard to LBT normalization, eleven of 12 patients (92%) with a positive diagnosis of SIBO at baseline confirmed by LBT had a negative LBT at the end of treatment with rifaximin and ten (83%) were negative at T56. Nine of them had a negative LBT both at the end of 14 days of treatment and at end of follow-up (T56).
Eight of the eleven patients who had a negative LBT at the end of treatment, and seven of the nine patients who had a negative LBT both at T14 and at T56, achieved an overall relief of IBS symptoms. A summary of clinical and hydrogen breath testing results, and the relationship between clinical response and hydrogen breath test are shown in Table 1 . 
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Molecular data
The fecal samples collected from all enrolled non-C IBS (ie, 15) patients and HS were processed according to the Material and methods section. All the values obtained from RT-PCR are reported in Table 2 . At T0, the mean levels of Bifidobacteria and Enterobacteriaceae in HS were similar to the mean values calculated for IBS subjects across each collection time.
In IBS patients, a general stability of the investigated groups across the different time points was observed: any fluctuation of Bifidobacterium spp., Enterobacteriaceae, Firmicutes, and Bacteroidetes seemed to be subject-related, even though an increasing trend over time was observed for Enterobacteriaceae ( Table 2) .
DGGE analyses confirmed that rifaximin did not significantly affect the overall composition of the core microbiota, as shown by uniformity of bands abundance and richness in the 15 subjects and across the three sampling time points (average number of dominant bands at T0=22±6.4, T14=20±7.0 and T56=21±6.6; for HS average number of bands was 23±5.3).
Similarity comparison between different sampling times in the same subject, calculated through Dice's coefficients (T0 vs T14 80±5.7%; T14 vs T56 85±12%; T56 vs T0 77±13%) suggested that rifaximin treatment did not induce relevant and measurable changes in the core microbiota. However, fluctuations at the level of specific bacterial populations at T14 samples were observed in clostridial representatives (eight out of 15 patients) and Faecalibacterium prausnitzii sequences (four out of 15 patients).
high-throughput sequencing-based diversity screening High-throughput sequencing was performed, in order to confirm and further analyze data obtained with RT-PCR and DGGE analysis. Figure 1 reports the hierarchical clustering of classified sequences, performed using the average linkage algorithm according to the order-family classifications for taxa participating with $10% in at least one sample. Taxa with lower participations were added to the "other" sequence group. The obtained clustering clearly showed that Lachnospiraceae and Ruminococcaceae dominated the majority of the surveyed microbial communities followed in abundance by Bacteroidaceae and Veillonellaceae ( Figure 2A ). Bacteroidetes were more abundant in IBS samples (T0: 5.58%, T14: 9.49%, T56:11.7%) compared to HS (4.92%), whereas Bifidobacteria were lower in IBS samples (T0: 2.11%, T14: 1.41%, T56: 1.67%) than in HS (5.34%).
Genus-related pie charts of HS ( Figure 2B ) showed a lower presence of Roseburia and Faecalibacterium in HS compared to IBS subjects, being the former 6.52% vs 14.4% and the latter 3.42% vs 5.66% respectively. Moreover at the end of the rifaximin treatment (T14), Faecalibacterium was increased (T14: 8.50% vs T0: 5.58%).
As shown in Figure 3 , the IBS sample bacterial communities had reduced diversity (Simpson's D). The average values of this coefficient were higher in HS (18.2) than IBS subjects (16.1), with a slight increasing trend from T0 to T56, leading to the hypothesis of a recovery in bacterial species differentiation after rifaximin intervention. This observation could also be inferred by the pie charts (Figure 2A and B) , where the compositions of the bacterial communities at T0 are similar to those at T56.
Clustering analysis did not suggest a particular treatment/time-wise grouping of the surveyed communities at taxonomical levels as low as the genus level ( Figure 2B) . Results of distance-based redundancy analysis showed that the combined effect of subject and sampling time contributed to 68.6% of the total variance between samples, but with most of it being attributed to the subject factor (94.3% of the explained variance, P,0.001) and only a small portion (5.7% of the explained variance, P=0.028) associated with the sampling time (antibiotic-associated effect) (Figure 4) .
Pairwise comparisons between samples of different experimental time points and with HS showed significantly lower participation of Clostridiaceae at T14 compared to T0 and T56. Bacteroidaceae increased in IBS subjects during the course of the trial and compared to HS. Enterobacteriaceae 
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soldi et al had higher abundance in IBS subjects compared to HS. Significant differences were found also in Streptococcaceae, that decreased in IBS patients over time; on the contrary Prevotellaceae were more represented in IBS samples than in HS, particularly after rifaximin treatment ( Figure 5 ). Maximum likelihood phylogeny showed that Otu0020, that resided in the same clade of Clostridium bartlettii, decreased from 2% to an almost undetectable amount of sequences at T14 and recovered to 1% at T56 ( Figure 5 ). Other OTUs with significant variations (Otu0002, Otu0010, Otu0016, and Otu0017) corresponded to F. prausnitzii (from 5.6% at T0 to 8.5% at T14), Roseburia inulinivorans (from 2.4% at T0 to 1.9% at T56), Streptococcus salivarius/ vestibularis (from 1% at T0 to 0.4% at T14, followed by a recovery to 1.9% at T56), and Blautia luti (from 1.6% at T0 to 0.7% at T14). Core bacteriome analysis between HS and the different sampling times in the IBS patients yielded 15 OTUs shared among all core bacteriomes (Table 3 ). The number of core bacteriome OTUs was reduced according to the ranking order: HS (13 OTUs) . T0 (ten OTUs) . T14 (six OTUs) . T56 (five OTUs). Thus, resulting in a condensation trend along time and treatment of the core bacteriome. Most OTUs were affiliated with the Firmicutes phylum, especially represented in the gut environment, and just two out of 15 OTUs were included in Bacteroidetes phylum. Five out of 15 OTUs participated in all core bacteriomes with their family/genus level taxonomical affiliations belonging to Roseburia, Faecalibacterium, Bacteroides, Anaerostipes, Lachnospiraceae. The described core bacteriome condensation corresponded to a trend of reduction in the within-sample diversity as shown by the obtained inverse Simpson's D values ( Figure 3 ) and an increased between-subject bacterial community structural 
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non-constipated iBs subjects treated with rifaximin variability (β-diversity) for samples derived from the IBS patients, as confirmed by the distance-based redundancy analysis results (Figure 4 ). For assessing potentially informative bacterial associations throughout all samples, we performed a Spearman's rank correlation test between bacterial taxonomical annotations followed by hierarchical clustering of the obtained correlation values. Two major groups of taxa were formed according to the Spearman's rank correlation test (Figure 6 ). The first one included the Ruminococcaceae, Alistipes and Oscillibacter taxa, which were positively correlated with each other and mainly negatively correlated with Escherichia and Veillonella, while Oscillibacter was also negatively correlated with Blautia. The second major cluster was divided into three subclusters as follows: the Clostridium, Bifidobacterium, Lachnospiraceae incertae sedis (IS), Blautia, Roseburia and Figure 2 Pie charts of the community compositions of samples derived from iBs patients and healthy subjects.
Notes:
The mean values of the major order/family level taxa (A) and genera (B) are presented for each study group. T0: baseline; T14: at the end of 14 days of treatment; T56: at the end of the 6-week follow-up period. Abbreviations: iBs, irritable bowel syndrome; HS, healthy subjects; IS, incertae sedis; Unc, unclassified. 39 Comparison of the means of this ratio between sampling groups or subjects did not show significant differences, as already shown by RT-PCR. However, a larger dispersal of values for the HS and IBS subjects at T0 was observed in particular compared to T14, indicating an overall condensation around low ratio values, following the treatment with rifaximin (Figure 7) . At T14, Firmicutes components displayed a slight increase, after the treatment, whereas Bacteroidetes group presented a def initely more important increase in their relative abundance, as shown in Figure 2A T0   S001  S002  S003  S004  S005  S006  S007  S008  S009  S010  S011  S012  S013  S014  S015 T14 T56 Figure 4 Distance-based redundancy analysis (rDa) showing the combined effect of subject and sampling time on the composition of the bacterial communities. Notes: The total variance explained by the model along with its partition into the model components are reported in the plot above. Model explained variance: 68.6% (P=0.005) of total: subject variance 94.3% (P=0) of explained, time variance 5.7% (P=0.028) of explained. T0: baseline; T14: at the end of 14 days of treatment; T56: at the end of the 6-week follow-up period. Abbreviation: s, subject. The condensation of the ratio around low values at T14 could be partially explained by the decrease of Clostridium spp. (belonging to Firmicutes phylum) that are highly sensitive to rifaximin antibacterial activity.
archaea Almost all retrieved sequences (99.9%) were classified up to the family-genus level. The vast majority of the archaeal dataset sequences were classified in the Methanobrevibacter genus with the representative sequence of the dominant OTU being phylogenetically affiliated to Methanobrevibacter smithii. No particular grouping of the samples was obtained according to the taxonomy analysis.
No differences were observed between HS and IBS patients (T0) and no modifications were induced by the rifaximin treatment.
Discussion
Epidemiological, physiological, and clinical data support bacteria as a key player in IBS ethiopathogenesis. 40, 41 Studies taking advantage of the new molecular biology techniques have highlighted distinct differences in the quality, quantity, and temporal stability of the gut microbiota in IBS patients when compared to HS. [4] [5] [6] [7] [8] Modifications of the gut microbiota were also reported in IBS patients with an imbalance of Firmicutes/Bacteroidetes ratio that is likely to have an impact on gas and metabolite 
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soldi et al production such as short chain fatty acids, thus on gut motility and bloating. 42 While the gut microbiota is highly variable between individuals, 41 most of the studies reported an increase of Enterobacteriaceae in IBS patients associated with a decrease of Lactobacilli and F. prausnitzii.
2-4
This latter phenomenon could have negative reflections, as F. prausnitzii was shown to have significant anti-inflammatory activity. 43 In our study, all the results, obtained with different molecular techniques, pointed out that rifaximin treatment did not affect the overall composition of the core microbiota 
Size
B Taxonomy
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Ruminococcaceae(100); Faecalibacterium(100) Bacteria(100); Proteobacteria(100); Gammaproteobacteria(100); Enterobacteriales(100); Enterobacteriaceae(100); Enteric_Bacteria_cluster(100); Escherichia(100)
Otu0010
Bacteria(100); Actinobacteria(100); Actinobacteria(100); Actinobacteridae(100); Bifidobacteriales(100); Bifidobacteriaceae(100); Bifidobacterium(100)
Otu0002
Otu0016 12866
Otu0017 12339
Otu0020 11462
OTU
Otu0003 42466
Bacteria(100); Bacteroidetes(100); Bacteroidia(100); Bacteroidales(100); Bacteroidaceae(100); Bacteroides(100)
65495
Otu0001 102862 Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Roseburia(100) Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Ruminococcaceae(100); Incertae_Sedis(100) 32368 Otu0005 Otu0006 28183 27143 Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Anaerostipes(100)
Otu0004
Otu0007
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Incertae_Sedis(100)
Otu0008 22359 Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Blautia(100) Bacteria(100); Bacteroidetes(100); Bacteroidia(100); Bacteroidales(100); Rikenellaceae(100); Alistipes(100) 21207 Otu0009
19968
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Roseburia(100)
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Veillonellaceae(100); Dialister(100) Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Incertae_Sedis(100) 18242 Otu0012
Otu0013
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Veillonellaceae(100); Dialister(100) 15824 Otu0014
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Incertae_Sedis(100) 14005 Otu0015
Bacteria(100); Firmicutes(100); Bacilli(100); Lactobacillales(100); Streptococcaceae(100); Streptococcus(100) Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Blautia(100) Bacteria(100); Bacteroidetes(100); Bacteroidia(100); Bacteroidales(100); Rikenellaceae(100); Alistipes(100) 12228 Otu0018
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Incertae_Sedis(100) 11554 Otu0019
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Peptostreptococcaceae(100); Incertae_Sedis(100) Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Lachnospiraceae(100); Incertae_Sedis(100) 11395 Otu0021
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Veillonellaceae(100); Phascolarctobacterium(100) 11312 Otu0022
Bacteria(100); Firmicutes(100); Clostridia(100); Clostridiales(100); Ruminococcaceae(100); Oscillibacter(100) 10890 Otu0023
Bacteria(100); Bacteroidetes(100); Bacteroidia(100); Bacteroidales(100); Prevotellaceae(100); Prevotella(100) 10525 Otu0024
Clinical and Experimental Gastroenterology 2015:8 submit your manuscript | www.dovepress.com
Dovepress
319
non-constipated iBs subjects treated with rifaximin of the treated subjects but caused, instead, fluctuations in few bacterial groups, that were balanced by the replacement of disappeared species by homologs or complementary bacterial groups, harboring similar characteristics.
Rifaximin appeared to influence mainly potentially detrimental bacteria, such as Clostridium besides Peptostreptococcaceae and Escherichia. On the other hand, a 14-day treatment with rifaximin seemed to increase the presence of bacteria such as F. prausnitzii, increasingly recognized as able to positively impact on physiological functions and homeostasis of the gut by producing butyrate and inducing anti-inflammatory processes. 44 As reported in recent literature, the majority of the IBS subjects had an altered intestinal microbiota, when compared with healthy controls, but some of the IBS samples presented no abnormalities in their microbiota composition. 45 Therefore, there is an extreme variability in the composition of IBS-subtypes microbiota with a consequent difficulty in identifying common traits among subjects, as confirmed by our study.
The results of our study evidenced a decrease in the Firmicutes/Bacteroidetes ratio at T14 compared with those detected in HS and at T0 in IBS patients. Furthermore, as shown by high-throughput sequencing and inferred by DGGE, bacterial profiles with higher biodiversity were observed in samples collected during the follow-up to rifaximin treatment (T56), compared to T0 and T14 (Figure 2A, B and Figure 7) . However, these data did not reach a statistical significance, due, likely, to the limited sample size and the high inter-individual variability.
During the last decades, some works have tried to identify possible relationships existing between the presence of methanogens and specific human diseases (colorectal cancers, inflammatory bowel disease, IBS, obesity, constipation), investigating the role of Archaea but no consistent link has been established between these diseases and methanogens. The high presence of M. smithii has been linked to bacteria 46, 47 and enterotypes 48 detectable in adults, suggesting the nonspecific and symbiotic interaction of methanogens with other members of gut microbiota. The prevalence of M. smithii was 
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non-constipated iBs subjects treated with rifaximin well demonstrated in our study, but a significant difference in Archaea population among the subjects and during the study was not observed. This could be linked to several reasons: first, methanogenic Archaea are mainly known as insensitive to most of the antibiotics commonly used in human therapies 49, 50 because of the composition of their membrane and cell wall and, second, although methane is detected in 30%-50% of the healthy adult population worldwide, its production has been epidemiologically and clinically associated with constipation related diseases such as constipationpredominant IBS and chronic constipation.
Our study was conducted on non-C IBS subjects; this could have deeply influenced the possibility to detect significant changes in the Archaea population. Moreover, the role of its members, beneficial or deleterious, is still remaining to be determined.
It could be concluded that rifaximin did not induce radical changes in the microbiota composition of the subjects, but stimulated microbial reorganization in some populations toward a more diverse composition in terms of species/OTUs, harboring similar metabolic pathways or filling the same niche, in particular among short chain fatty acids producing bacteria.
In this regard, our findings on IBS subjects were in agreement with Maccaferri et al, 51 who concluded that alternative mechanisms of action not involving a direct bactericidal activity could explain the efficacy of rifaximin: for example, the alteration of virulence factors of enteric bacteria and the reduction of pathogen adhesion and internalization to intestinal epithelium. 52, 53 Moreover, rifaximin activates the human pregnane X receptor, resulting in upregulation of host detoxification mechanisms and regulation of inflammatory processes that may modulate host response to dysbiosis. 54, 55 A short course of rifaximin leads to sustained improvement of IBS symptoms; the antibiotic effect of rifaximin is the presumed mechanism for its sustained beneficial effects, even if the precise mechanism by which rifaximin is effective in the treatment of non-C IBS adults is unknown. However, based on current in vitro and in vivo data, there are some plausible explanations for rifaximin's clinical efficacy in IBS. 56 The response to rifaximin therapy was correlated with normalization of the results of lactulose hydrogen breath tests. Due to the limited sample size and the absence of a control group, it was not possible to speculate on differences of fecal microbiota modification between responders vs non-responders and to correlate the quali-/quantitative modification of upper GI microbiota and clinical response. The culture and molecular analysis of jejunal aspirates, if available, instead of fecal culture could probably have highlighted a possible correlation between rifaximin efficacy on SIBO and a quali-/quantitative modification of upper GI microbiota. In spite of the small sample size and the high variability between subjects, this is one of the first studies evaluating the modifications of intestinal microbiota in IBS patients after an antibiotic treatment.
Our results are also in agreement with the preliminary data of Pimentel et al 57 demonstrating, in a higher sample size that, during repeat treatment with rifaximin, no sustained disturbance of the stool microbiota was observed in non-C IBS subjects, who experienced persistent symptom improvement. 58 Moreover, rifaximin acts similarly in other pathologies such as hepatic encephalopathy: in fact, it was effective in patients with hepatic encephalopathy, inducing only a modest change in stool microbiota composition. [59] [60] [61] In conclusion rifaximin is efficacious without inducing dramatic shifts in the fecal microbiota composition. The primer-sets used in the first step were the E343f-E802r for bacteria and the A787f-A1053r for Archaea: sequences are reported in the upper part of Table S1 . They were then indexed with the 5′ sequence extensions, provided in the same table. The first-step polymerase chain reactions (PCRs) were performed in 25 µL volumes including 0.1 ng and 1 ng of template DNA extracts for bacteria and Archaea Ta  TTaTCCGTaTaCGGraGGCaGCaG  TTaTCCGTaaTTaGaTaCCCsBGTaGTCC  2 TTaTGGC Ta  TTaTGGCTaTaCGGraGGCaGCaG  TTaTGGCTaaTTaGaTaCCCsBGTaGTCC  3 TTaCaCC Ta  TTaCaCCTaTaCGGraGGCaGCaG  TTaCaCCTaaTTaGaTaCCCsBGTaGTCC  4 TTaCGTG Ta  TTaCGTGTaTaCGGraGGCaGCaG  TTaCGTGTaaTTaGaTaCCCsBGTaGTCC  5 TTaGaGG Ta  TTaGaGGTaTaCGGraGGCaGCaG  TTaGaGGTaaTTaGaTaCCCsBGTaGTCC  6 TTaGCTC Ta  TTaGCTCTaTaCGGraGGCaGCaG  TTaGCTCTaaTTaGaTaCCCsBGTaGTCC  7 TTCTTCC Ta  TTCTTCCTaTaCGGraGGCaGCaG  TTCTTCCTaaTTaGaTaCCCsBGTaGTCC  8 TTCTCGT Ta  TTCTCGTTaTaCGGraGGCaGCaG  TTCTCGTTaaTTaGaTaCCCsBGTaGTCC  9 TTCTGaG Ta  TTCTGaGTaTaCGGraGGCaGCaG  TTCTGaGTaaTTaGaTaCCCsBGTaGTCC  10 TTCaaCG Ta  TTCaaCGTaTaCGGraGGCaGCaG  TTCaaCGTaaTTaGaTaCCCsBGTaGTCC  11  TTCaGTC  Ta  TTCaGTCTaTaCGGraGGCaGCaG  TTCaGTCTaaTTaGaTaCCCsBGTaGTCC  12  TTCCaGa  Ta  TTCCaGaTaTaCGGraGGCaGCaG  TTCCaGaTaaTTaGaTaCCCsBGTaGTCC  13  TTCGTTG  Ta  TTCGTTGTaTaCGGraGGCaGCaG  TTCGTTGTaaTTaGaTaCCCsBGTaGTCC  14  TTCGCaa  Ta  TTCGCaaTaTaCGGraGGCaGCaG  TTCGCaaTaaTTaGaTaCCCsBGTaGTCC  15  TTGTCaC  Ta  TTGTCaCTaTaCGGraGGCaGCaG  TTGTCaCTaaTTaGaTaCCCsBGTaGTCC  16 TTGTGCT Ta  TTGTGCTTaTaCGGraGGCaGCaG  TTGTGCTTaaTTaGaTaCCCsBGTaGTCC  17  TTGaaGC  Ta  TTGaaGCTaTaCGGraGGCaGCaG  TTGaaGCTaaTTaGaTaCCCsBGTaGTCC  18  TTGaCTG  Ta  TTGaCTGTaTaCGGraGGCaGCaG  TTGaCTGTaaTTaGaTaCCCsBGTaGTCC  19  TTGCTaG  Ta  TTGCTaGTaTaCGGraGGCaGCaG  TTGCTaGTaaTTaGaTaCCCsBGTaGTCC  20 TTGGTGT Ta  TTGGTGTTaTaCGGraGGCaGCaG  TTGGTGTTaaTTaGaTaCCCsBGTaGTCC  21  TTGGaCa  Ta  TTGGaCaTaTaCGGraGGCaGCaG  TTGGaCaTaaTTaGaTaCCCsBGTaGTCC  22  TaTTCGC  Ta  TaTTCGCTaTaCGGraGGCaGCaG  TaTTCGCTaaTTaGaTaCCCsBGTaGTCC  23  TaTaGCC  Ta  TaTaGCCTaTaCGGraGGCaGCaG  TaTaGCCTaaTTaGaTaCCCsBGTaGTCC  24  TaaCCaC  Ta  TaaCCaCTaTaCGGraGGCaGCaG  TaaCCaCTaaTTaGaTaCCCsBGTaGTCC  25  TaaGGaG  Ta  TaaGGaGTaTaCGGraGGCaGCaG  TaaGGaGTaaTTaGaTaCCCsBGTaGTCC  26  TaCTCCa  Ta  TaCTCCaTaTaCGGraGGCaGCaG  TaCTCCaTaaTTaGaTaCCCsBGTaGTCC  27  TaCaCaG  Ta  TaCaCaGTaTaCGGraGGCaGCaG  TaCaCaGTaaTTaGaTaCCCsBGTaGTCC  28  TaCCGaa  Ta  TaCCGaaTaTaCGGraGGCaGCaG  TaCCGaaTaaTTaGaTaCCCsBGTaGTCC  29  TaGTaCC  Ta  TaGTaCCTaTaCGGraGGCaGCaG  TaGTaCCTaaTTaGaTaCCCsBGTaGTCC  30  TaGTGTG  Ta  TaGTGTGTaTaCGGraGGCaGCaG  TaGTGTGTaaTTaGaTaCCCsBGTaGTCC  31  TaGCCTa  Ta  TaGCCTaTaTaCGGraGGCaGCaG  TaGCCTaTaaTTaGaTaCCCsBGTaGTCC  32 TCTaCCT Ta  TCTaCCTTaTaCGGraGGCaGCaG  TCTaCCTTaaTTaGaTaCCCsBGTaGTCC  33  TCaaGCa  Ta  TCaaGCaTaTaCGGraGGCaGCaG  TCaaGCaTaaTTaGaTaCCCsBGTaGTCC  34  TCaCaaG  Ta  TCaCaaGTaTaCGGraGGCaGCaG  TCaCaaGTaaTTaGaTaCCCsBGTaGTCC  35 TCaGaCT Ta  TCaGaCTTaTaCGGraGGCaGCaG  TCaGaCTTaaTTaGaTaCCCsBGTaGTCC  36  TGTTGCa  Ta  TGTTGCaTaTaCGGraGGCaGCaG  TGTTGCaTaaTTaGaTaCCCsBGTaGTCC  37  TGTaCTC  Ta  TGTaCTCTaTaCGGraGGCaGCaG  TGTaCTCTaaTTaGaTaCCCsBGTaGTCC  38 TGTaGGT Ta  TGTaGGTTaTaCGGraGGCaGCaG  TGTaGGTTaaTTaGaTaCCCsBGTaGTCC  39  TGTGTaG  Ta  TGTGTaGTaTaCGGraGGCaGCaG  TGTGTaGTaaTTaGaTaCCCsBGTaGTCC  40  aTTaGCG  Ta  aTTaGCGTaTaCGGraGGCaGCaG  aTTaGCGTaaTTaGaTaCCCsBGTaGTCC  41  aTTCCTC  Ta  aTTCCTCTaTaCGGraGGCaGCaG  aTTCCTCTaaTTaGaTaCCCsBGTaGTCC  42  aTTGaCC  Ta  aTTGaCCTaTaCGGraGGCaGCaG  aTTGaCCTaaTTaGaTaCCCsBGTaGTCC  43  aTCTGCa  Ta  aTCTGCaTaTaCGGraGGCaGCaG  aTCTGCaTaaTTaGaTaCCCsBGTaGTCC  44  aTGaGGa  Ta  aTGaGGaTaTaCGGraGGCaGCaG  aTGaGGaTaaTTaGaTaCCCsBGTaGTCC  45  aaTTCCG  Ta  aaTTCCGTaTaCGGraGGCaGCaG  aaTTCCGTaaTTaGaTaCCCsBGTaGTCC  46  aaTCGTG  Ta  aaTCGTGTaTaCGGraGGCaGCaG  aaTCGTGTaaTTaGaTaCCCsBGTaGTCC  47  aGTTGaG  Ta  aGTTGaGTaTaCGGraGGCaGCaG  aGTTGaGTaaTTaGaTaCCCsBGTaGTCC  48  aGCaGaa  Ta  aGCaGaaTaTaCGGraGGCaGCaG  aGCaGaaTaaTTaGaTaCCCsBGTaGTCC  49 CTTGaGT Ta  CTTGaGTTaTaCGGraGGCaGCaG  CTTGaGTTaaTTaGaTaCCCsBGTaGTCC  50 CTCCaaT Ta CTCCaaTTaTaCGGraGGCaGCaG CTCCaaTTaaTTaGaTaCCCsBGTaGTCC
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